To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad
Age 18 years-65 years
Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity)
Disease duration of at least 6 months
Willing and able to provide written informed consent
Severe psoriasis (BSA >20% or requiring systemic therapy)
Pregnant and lactating mothers
Known hypersensitivity to Tapinarof or any of its excipients
Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis
Parallel
Betamethasone Dipropionate 0.05% Cream
DrugTopical betamethasone dipropionate 0.05% cream once daily applied to affected plaque psoriasis lesions twice daily for up to 4 weeks
Tapinarof Cream 1%
DrugTopical tapinarof 1% cream applied once daily to affected skin areas for up to 12 weeks
Percentage of participants achieving a 75% reduction from baseline in psoriasis area and severity index(PASI 75)
The psoriasis area and severity index(PASI) quantifies the severity of psoriasis plaques and the total body surface area affected.It combines assessments of plaque erythema, induration and desquamation across four body regions (head, trunk, upper limbs, lower limbs ) into a score ranging from 0 ( no disease) to 72 ( severe disease) .PASI 75 represents a 75% or greater reduction ( improvement) in the total PASI score compared to the participants baseline value.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
